Filing identity and reporting period
The supplied filing is Rexahn Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2015—not a filing identified as Opus Genetics, Inc. It reports second-quarter and six-month 2015 results, with comparisons to 2014.
Business context
Rexahn describes itself as a clinical-stage biopharmaceutical company focused on oncology and other serious conditions. Its pipeline included one Phase II candidate, two Phase I candidates, and preclinical programs. The company had no product sales and expected operating losses to continue.
Financial performance and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $0 in 2015 and 2014 | $0 in 2015 and 2014 |
| R&D expense | $3.24 million in 2015; $1.70 million in 2014 | $6.13 million in 2015; $2.97 million in 2014 |
| G&A expense | $1.58 million in 2015; $1.81 million in 2014 | $3.11 million in 2015; $3.30 million in 2014 |
| Net income (loss) | $(3.23) million in 2015; $0.19 million in 2014 | $(7.51) million in 2015; $(14.41) million in 2014 |
| Operating cash flow | Not separately provided for the quarter | $(8.44) million in 2015; $(5.53) million in 2014 |
At June 30, 2015, cash and cash equivalents were $9.97 million and marketable securities were $16.01 million, totaling $25.98 million, down from $32.70 million at December 31, 2014. Current liabilities were $5.94 million; total liabilities included $2.09 million of warrant liabilities, and the filing shows no conventional borrowings. Stockholders’ equity was $21.43 million. No profit margin is meaningful given zero revenue.
Material changes and unusual items
Second-quarter R&D expense rose 90.1% year over year, and six-month R&D expense more than doubled, reflecting clinical-trial, drug-manufacturing, and personnel costs as Archexin, RX-3117, and Supinoxin advanced. G&A declined 12.3% in the quarter and 5.8% for the half year, primarily due to lower professional fees, partly offset by higher personnel expense.
Warrant fair-value accounting materially affected reported earnings: the company recorded a $1.56 million gain in Q2 2015 and a $1.67 million gain for the first half, versus a $7.995 million loss for the first half of 2014. These noncash gains contributed to the year-over-year improvement in the six-month net loss. In Q2 2014, a $3.67 million warrant gain helped produce reported net income despite operating losses.
Financing cash inflows were $1.71 million in the first half of 2015, versus $24.84 million in the first half of 2014. The 2015 amount included $1.01 million net proceeds from stock sales under an at-the-market agreement and $0.71 million from option exercises. The agreement permits up to $40 million of common-stock sales, with a 3% sales commission; use is optional and additional proceeds are not assured.
Outlook, risks, and contingencies
Management said cash, cash equivalents, and marketable securities were expected to cover current-activity cash needs for at least 12 months. It also said additional capital would be needed to continue drug development; if financing is unavailable or unsatisfactory, R&D activities may be reduced. Management anticipated losses through 2015 and beyond.
The company planned to complete the initial safety component of the Archexin renal-cell-carcinoma study in the second half of 2015 and expected to present preliminary Phase Ib findings for RX-3117 and Supinoxin in Q3 2015. Maximum tolerated doses had not been reached for either RX-3117 or Supinoxin, and timing of completion was uncertain. RX-21101 was preclinical and had been selected for the National Cancer Institute’s nanotechnology characterization program.
Key risks include clinical and regulatory uncertainty, reliance on external research organizations and collaborators, manufacturing and trial delays, intellectual-property risks, and the need for further financing. Estimated costs to complete contracted R&D vendor agreements were approximately $9.67 million. A $1 million KRICT milestone payment and potential milestones under two drug-delivery platform licenses had not been triggered. The filing states that disclosure controls were effective and that no material change in internal control over financial reporting occurred during the quarter.
Important facts for investors to verify
- Confirm the issuer: the source filing names Rexahn Pharmaceuticals, Inc., while the request metadata names Opus Genetics, Inc.
- Assess whether the reported cash runway remains adequate against operating cash use, trial spending, and the company’s stated need for additional capital.
- Check subsequent clinical updates for Archexin, RX-3117, and Supinoxin, including enrollment, safety findings, and progress toward dose milestones.
- Monitor stock issuance under the $40 million at-the-market agreement and potential dilution from outstanding options and warrants.
- Review the sensitivity of reported earnings and warrant liabilities to fair-value assumptions; the warrant valuation uses significant unobservable inputs.